Neurotoxicity Characterized After Infusion of CD19 CAR-T Cells

Share this content:
Neurotoxicity Characterized After Infusion of CD19 CAR-T Cells
Neurotoxicity Characterized After Infusion of CD19 CAR-T Cells

THURSDAY, Oct. 12, 2017 (HealthDay News) -- Patients with severe neurotoxicity after infusion of CD19-targeted chimeric antigen receptor-modified T (CAR-T) cells have evidence of endothelial activation, according to a study published online Oct. 12 in Cancer Discovery.

Juliane Gust, M.D., Ph.D., from the University of Washington in Seattle, and colleagues characterized neurologic adverse events in 133 adults with refractory B-cell malignancies treated with lymphodepletion chemotherapy followed by infusion of CD19 CAR-T cells.

The researchers found that there were correlations for acute lymphoblastic leukemia, high CD19+ cells in bone marrow, high CAR-T cell dose, cytokine release syndrome, and pre-existing neurologic comorbidities with elevated risk of neurologic adverse events. There was evidence of endothelial activation among patients with severe neurotoxicity, including disseminated intravascular coagulation, capillary leak, and elevated blood-brain barrier (BBB) permeability. The permeable BBB did not protect the cerebrospinal fluid from high concentrations of systemic cytokines, including interferonγ, which induced brain vascular pericyte stress and secretion of endothelium-activating cytokines. The brain of a patient with fatal neurotoxicity had endothelial activation and multifocal vascular disruption. In patients who subsequently developed grade ≥ 4 neurotoxicity, biomarkers of endothelial activation were higher before treatment.

"We show endothelial dysfunction and increased BBB permeability in neurotoxicity and find that patients with evidence of endothelial activation before lymphodepletion may be at increased risk of neurotoxicity," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry, including Juno Therapeutics, which partially funded the study.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Characteristics of Severe Hypoglycemia Identified in T2DM

Characteristics of Severe Hypoglycemia Identified in T2DM

Increased odds of severe hypoglycemia with history of non-severe hypoglycemia, HbA1c <6 percent

Hand-Holding, Stress Ball Don't Cut Anxiety in Skin CA Removal

Hand-Holding, Stress Ball Don't Cut Anxiety in Skin ...

No incremental anxiety reduction versus control in patients during excisional skin cancer surgery

L-Glutamine Reduces Number of Pain Crises in Sickle Cell Disease

<small>L</small>-Glutamine Reduces Number of Pain Crises in Sickle ...

Significantly fewer pain crises, hospitalizations compared with those receiving placebo

is free, fast, and customized just for you!




Already a member?

Sign In Now »